Table of Contents
License-out vs. License-in: How to Design International BD Strategies for Healthcare Companies?
In the global healthcare industry, License-out and License-in have become important tools for companies to conduct innovative asset transactions, international commercialization, and industrial cooperation.
For companies with innovative drugs, medical devices, diagnostic products, or other healthcare technology assets, international BD (Business Development) is not just about finding an overseas company to sign a cooperation agreement, but about solving three core problems:
- What assets are suitable for License-out?
- Under what circumstances should external innovative assets be acquired through License-in?
- How to design regional rights, transaction structures, and partners to match the asset value with the corporate strategy?
Simply put, License-out is when a company licenses the product, technology, or regional commercial rights it owns to a partner in exchange for upfront payments, milestone payments, sales royalties, or other economic benefits; License-in is when a company obtains the development, registration, production, or commercialization rights of a specific product or technology from an external asset owner.
These two models are not a simple “seller” and “buyer” relationship. For healthcare companies, what is truly important is to design transactions around asset value, market regions, life cycles, commercialization capabilities, and long-term strategies.
I. What are License-out and License-in?
License-out: Pushing Innovative Assets into Overseas Markets
License-out usually refers to a healthcare company, as the asset rights holder, licensing the development, registration, production, or commercialization rights of a certain product, technology, or intellectual property in a specific region to another company.
For example, a Chinese innovative drug company owns the global rights to a certain drug candidate, and can choose to:
- Enter overseas markets on its own;
- License the rights in certain regions outside of China to overseas pharmaceutical companies;
- License the development and commercialization rights in specific countries or regions to partners;
- Jointly promote the product through joint development or regional licensing.
The core of License-out is not simply selling assets, but realizing the value of assets in overseas markets through the capital, R&D, registration, channels, and commercialization capabilities of partners.
A typical economic arrangement may include:
- Upfront Payment
- Development Milestones
- Regulatory Milestones
- Commercial Milestones
- Royalties
- Profit Sharing
- Equity Investment
- Co-development / Co-commercialization
The specific structure needs to be determined based on the asset stage, regional rights, partner capabilities, and the development and commercialization responsibilities undertaken by both parties.
License-in: Introducing External Innovative Assets
License-in is when a company obtains the development, registration, production, or commercialization rights of a certain product, technology, or intellectual property in a specific market from an external asset owner.
For healthcare companies with mature commercialization systems, sales channels, or registration capabilities, License-in can help them to:
- Expand their product pipeline;
- Acquire new technology platforms;
- Quickly enter new therapeutic areas;
- Supplement the product life cycle;
- Obtain overseas innovative assets;
- Enhance regional market competitiveness.
Therefore, License-in is not equivalent to “buying a product.”
More accurately, License-in is a strategic tool to supplement a company’s internal R&D and product pipeline with external innovative assets.
II. What Problems are License-out and License-in Suitable for Solving?
Before a company designs its international BD strategy, it first needs to clarify what problem the transaction is intended to solve.
License-out mainly solves four types of problems
First, to solve the problem of insufficient overseas commercialization capabilities.
If a company has innovative assets but lacks overseas registration, sales, and commercialization teams, then licensing regional rights to local partners may be more direct than building a complete overseas commercial system on its own.
Second, to improve the capital efficiency of innovative assets.
R&D companies can obtain upfront payments, milestone payments, and future sales royalties through License-out, converting assets that have not been fully commercialized into phased cash flows and long-term equity.
Third, to reduce the cost of international development.
There are significant differences in the clinical, registration, access, and commercialization systems of different countries. Introducing partners familiar with the local market can share some of the development and commercialization investment.
Fourth, to leverage the resources of industrial partners to amplify the value of assets.
The value of an innovative product depends not only on the technology itself, but also on clinical development, registration, payment systems, physician networks, sales channels, and commercialization execution capabilities.
License-in mainly solves three types of problems
First, to supplement the internal R&D pipeline.
Companies can acquire external assets that have completed a certain stage of R&D through License-in, thereby shortening the internal R&D cycle.
Second, to enter new therapeutic areas or product areas.
If a company has established a mature commercialization system, but its internal R&D capabilities cannot cover a certain new area, it can supplement its product portfolio through License-in.
Third, to obtain international innovative assets.
For companies with commercialization capabilities in the Chinese market, introducing products from overseas innovative companies is a way to enter new product areas and build international BD capabilities.
III. What Should International BD Answer First: What Does the Company Really Need?
Many companies tend to start with “what projects can we cooperate on” when conducting License transactions.
A more effective way is usually the other way around:
First determine the corporate strategy, then look for matching assets.
Before launching international BD, a company can first answer the following questions:
1. What is the company’s product strategy for the next 3-5 years?
It needs to be clear:
- Core therapeutic areas;
- Key product types;
- Target patient groups;
- Target markets;
- Product life cycle;
- Commercialization model.
If the strategic direction is not clear, License-in is likely to become “we want to introduce any good project we see.”
2. What does the company lack most?
It is necessary to distinguish between:
- Product gap;
- Technology gap;
- Market gap;
- Geographical gap;
- Registration capability gap;
- Commercialization capability gap;
- R&D capability gap.
Different gaps correspond to different BD strategies.
For example:
Lack of products → License-in
Lack of overseas commercialization capabilities → License-out
Lack of regional partners → Strategic Partnership
Need for joint development → Co-development
Therefore, License is not the only international BD model.
IV. What Kind of Healthcare Assets are Suitable for License-out?
Not all innovative assets are suitable for immediate License-out.
It usually needs to be evaluated from the following dimensions.
1. Technology and Product Differentiation
Partners usually need to judge:
- Whether the technology is differentiated;
- Whether the product solves a clear clinical need;
- What advantages it has compared to existing treatment options;
- Whether there are clear competing products;
- Whether the intellectual property has protective capabilities.
For innovative drugs, further analysis is needed on:
- Target;
- Mechanism of action;
- Clinical stage;
- Clinical data;
- Safety;
- Efficacy;
- Unmet clinical needs.
For medical devices, attention should be paid to:
- Technology barriers;
- Clinical value;
- Registration pathway;
- Product iteration capability;
- Competitive landscape;
- Commercialization channels.
2. Product Development Stage
The BD strategy for an asset usually differs depending on its stage.
For example:
Early R&D Stage
The transaction focus may be more on:
- Scientific basis;
- Patents;
- Target or technology platform;
- Subsequent development potential.
Clinical Stage
The transaction evaluation will focus more on:
- Clinical data;
- Safety;
- Efficacy;
- Clinical development pathway;
- Competitive landscape.
Registration or Commercialization Stage
Partners usually focus more on:
- Registration status;
- Market size;
- Pricing;
- Channels;
- Sales forecast;
- Commercialization costs.
Therefore, a company cannot simply think that “the earlier the License-out, the better” or “the later the License-out, the better.”
What really needs to be considered is:
How much development risk can the company itself bear, and what stage is most suitable for introducing a partner.
V. Regional Rights are the Core of International License Transaction Design
In international License transactions, a very important question is:
Which regions should be licensed?
A company can choose different regional models based on its own strategy.
For example:
- Global rights;
- Greater China;
- Global rights excluding China;
- North America;
- Europe;
- Japan;
- Southeast Asia;
- Middle East;
- Specific countries.
The design of regional rights directly affects the asset value and transaction structure.
What is the difference between a global License and a regional License?
If a company licenses its global rights as a whole, the transaction structure may be simpler, but the company’s future control over other markets will also be correspondingly reduced.
If a regional License is adopted, the company can:
- Operate its core market on its own;
- License non-core markets to partners;
- Find different partners for different regions;
- Retain some commercialization rights.
For companies with strong local commercialization capabilities, “self-operation in core markets + overseas regional licensing” may be a structure worth evaluating.
But whether it is suitable needs to be judged based on the company’s financial strength, overseas team, registration capabilities, and asset stage.
VI. How to Choose a License-out Partner?
International BD is not simply looking for “the largest pharmaceutical company.”
The size of the partner does not equal the value of the cooperation.
What is more important is whether the partner matches the asset and the target market.
It can be evaluated from the following six aspects.
1. Therapeutic Area Capability
Has the partner been focusing on this disease area for a long time?
2. Registration Capability
Does it have registration and regulatory experience in the target market?
3. Commercialization Capability
Does it have:
- A sales team;
- Hospital channels;
- A physician network;
- Market access capabilities;
- Product promotion capabilities.
4. Financial Capability
Can the partner bear the subsequent:
- Clinical development;
- Registration;
- Production;
- Market promotion;
- Commercialization investment.
5. Strategic Fit
Does this asset belong to the partner’s future product strategy?
6. Willingness to Execute
Does the partner really have the resources to advance the project, rather than just shelving it for a long time after obtaining the license?
Therefore, the goal of international BD is not to find “the most well-known company,” but to find a partner who can truly realize the value of the asset.
VII. How to Screen for License-in Projects?
For License-in, the core problem faced by the company is different.
It is not “who can I sell my assets to,” but:
Which external assets are truly worth entering my product pipeline?
It is recommended to establish a clear project screening system.
First Layer: Strategic Fit
Does the project conform to:
- The company’s therapeutic area;
- The product strategy;
- The commercialization capabilities;
- The market layout.
If the project is completely inconsistent with the company’s long-term strategy, even if the technology is excellent, it needs to be evaluated with caution.
Second Layer: Clinical and Technical Value
Focus on analyzing:
- Clinical data;
- Safety;
- Efficacy;
- Technical differentiation;
- Unmet needs;
- Competing products.
Third Layer: Commercial Value
It is necessary to evaluate:
- Target patient population;
- Market size;
- Pricing space;
- Commercialization costs;
- Channel construction;
- Market competition.
Fourth Layer: Transaction Value
Finally, it is also necessary to judge:
Does the asset value match the transaction price?
A project with good technical prospects does not mean that any transaction price is reasonable.
Therefore, a License-in project needs to be looked at simultaneously:
Scientific Value + Clinical Value + Commercial Value + Transaction Structure.
VIII. How Should the Economic Structure of a License Transaction be Designed?
A License transaction is usually not a single-price transaction.
A typical structure may include:
Upfront + Milestones + Royalties
That is:
Upfront Payment + Milestone Payments + Sales Royalties
For example, the transaction can set payments according to different stages:
Signing
Pay the Upfront.
Clinical Development
Pay a Milestone after reaching a specific clinical development milestone.
Obtaining Regulatory Approval
Pay a Milestone after reaching a registration milestone.
Commercialization
Pay a Commercial Milestone after reaching a specific sales target.
Product Sales
Pay a Royalty according to the agreed proportion.
The significance of this structure is:
To link the transaction risk with the future progress of the project.
This is particularly important for early-stage assets, as the future of the project has greater development uncertainty.
IX. Besides the Price, What Else Needs to be Negotiated?
License transaction negotiations cannot only revolve around the Upfront.
Much of the long-term value actually comes from other clauses in the contract.
For example:
- Licensed territory;
- Exclusive / Non-exclusive;
- Right to sublicense;
- Development obligations;
- Registration obligations;
- Commercialization obligations;
- Minimum investment requirements;
- Definition of milestones;
- Royalty rate;
- Ownership of intellectual property;
- Rights to improved technology;
- Right to use data;
- Termination clause;
- Change of Control;
- Exit mechanism.
Among them, special attention should be paid to:
After the partner obtains the rights, must they advance the development and commercialization within the agreed time?
If there is a lack of clear development and commercialization obligations, the asset may be shelved for a long time.
X. International BD Due Diligence Cannot Only Look at Technical Data
Due diligence in License transactions usually needs to span multiple dimensions.
Legal and Intellectual Property
Including:
- Patent ownership;
- Patent validity period;
- Patent territory;
- Patent litigation;
- Third-party rights;
- License chain.
Technology and R&D
Including:
- Clinical data;
- R&D records;
- Trial design;
- Safety;
- Efficacy;
- Technical risks.
Registration
Including:
- Current registration status;
- Regulatory pathway in the target market;
- Existing regulatory communications;
- Potential registration barriers.
Commercial
Including:
- Market size;
- Competitive landscape;
- Pricing;
- Commercialization costs;
- Sales forecast.
Transaction
Including:
- Existing licenses;
- Regional rights;
- Existing cooperation agreements;
- Payment obligations;
- Future transaction restrictions.
Therefore, License due diligence is essentially a comprehensive judgment process across technology, clinical, legal, registration, commercial, and transaction structures.
XI. How Can Chinese Healthcare Companies Design Their International BD Path?
For Chinese healthcare companies hoping to enter the international market, international BD can be broken down into five stages.
First Stage: Asset Sorting
Establish an Asset Map:
- Products;
- Technology;
- Patents;
- Clinical stage;
- Registration status;
- Target market;
- Current rights structure.
Second Stage: Determine BD Goals
Clarify what the company really wants to obtain:
- Cash flow;
- Overseas markets;
- R&D resources;
- Commercialization capabilities;
- Strategic investment;
- Global partners.
Third Stage: Establish a Partner List
Establish a potential partner database according to the target market.
You can screen from different types of companies such as:
- Large pharmaceutical companies;
- Professional Biotech;
- Medical device companies;
- Regional commercialization companies;
- Companies in specialized fields;
- Strategic investors.
Fourth Stage: Design the Transaction Structure
Design based on the asset stage and partner situation:
- License-out;
- License-in;
- Co-development;
- Co-commercialization;
- Joint Venture;
- Strategic Investment;
- Regional Partnership.
Fifth Stage: Transaction Execution
International BD ultimately needs to enter this process:
Contact → NDA → Teaser → Management Presentation → Data Room → Due Diligence → Term Sheet → Definitive Agreement → Closing
Therefore, international BD is not a simple business introduction, but a complete transaction process.
XII. How to Choose Between License-out and License-in?
A simple strategic framework can be used for judgment.
| Company Situation | More Worthwhile Direction to Evaluate |
|---|---|
| Has innovative assets, but limited overseas commercialization capabilities | License-out |
| Has mature overseas commercialization channels | License-in / Co-commercialization |
| Hopes to obtain overseas cash flow | License-out |
| Hopes to quickly supplement the product pipeline | License-in |
| Hopes to enter new therapeutic areas | License-in |
| Hopes to reduce overseas development costs | License-out |
| Hopes to retain control of the core market | Regional License |
| Hopes to jointly bear R&D risks | Co-development |
| Hopes to establish long-term industrial relationships | Strategic Partnership / JV |
This table is not a fixed answer.
The same company may also adopt both License-out and License-in for different products, different markets, and at different stages of development.
XIII. The Most Important Thing in International BD is Not the “Transaction,” but the “Strategic Fit”
A successful License transaction usually needs to satisfy the matching at three levels simultaneously.
First Layer: Asset Matching
Does the product or technology have real value?
Second Layer: Market Matching
Can the partner achieve commercialization in the target market?
Third Layer: Strategic Matching
Does the transaction conform to the long-term development direction of both parties?
If there is only asset matching but no market matching, the transaction may be difficult to commercialize.
If there is only market matching but no strategic matching, the cooperative relationship may be difficult to sustain.
Therefore:
The core of international BD is not to find a partner willing to sign a contract, but to find a partner who can jointly realize the value of the asset.
XIV. Five Key Questions for Healthcare Companies When Designing International BD Strategies
Before launching a License-out or License-in, a company can first answer the following five questions:
1. What are we really trading?
Is it a product, technology, intellectual property, or the commercialization rights in a specific region?
2. Which regions should be licensed?
Is it a global license, or a regional license?
3. What type of partner is the best match?
Is it a large pharmaceutical company, a professional Biotech, a regional commercialization company, or an industrial investor?
4. How to allocate future risks and benefits?
How should it be designed:
- Upfront;
- Milestones;
- Royalties;
- Profit Sharing;
- Development Obligations.
5. Who is responsible for making the project a success after the transaction is completed?
This is an often-overlooked question in international BD.
What is really important is not the signing of the contract, but:
Who invests resources, who bears the development risks, who is responsible for registration, who is responsible for commercialization, and how the two parties share the final value.
Conclusion: From License Transactions to International Industrial Cooperation
For healthcare companies, License-out and License-in are not two isolated transaction models.
They are actually part of the company’s international BD strategy.
License-out helps companies connect their own innovative assets to overseas capital, R&D, and commercialization resources; License-in helps companies obtain external innovation capabilities, product pipelines, and market opportunities.
A truly mature international BD strategy needs to start from the overall corporate strategy and comprehensively consider:
Asset value, product stage, regional rights, partner capabilities, development risks, commercialization capabilities, and transaction structure.
For Chinese healthcare companies hoping to enter overseas markets, international BD should not be just about finding an overseas buyer, but should establish a continuous system of:
Asset Sorting → Market Selection → Partner Mapping → Transaction Design → Due Diligence → Negotiation Execution → Commercialization Synergy
When a company can further upgrade from “what assets can be traded” to “which assets should be cooperated with which type of partner in which market and with what structure,” License-out and License-in can truly become strategic tools for the company’s internationalization and long-term value creation.
FAQ: Common Questions about License-out and License-in
What is License-out?
License-out refers to a healthcare company licensing the development, registration, production, or commercialization rights of its owned products, technologies, or intellectual property in a specific region to other companies, and obtaining upfront payments, milestone payments, sales royalties, or other economic benefits according to the transaction agreement.
What is License-in?
License-in refers to a healthcare company obtaining the development, registration, production, or commercialization rights of a certain product, technology, or intellectual property in a specific market from an external asset owner to supplement its own product pipeline, technical capabilities, or market layout.
What is the difference between License-out and License-in?
License-out usually focuses on the company exporting its own innovative assets and regional rights, while License-in focuses on the company importing external products, technologies, or commercialization rights. Both are important tools for international BD and strategic cooperation for healthcare companies.
What payment methods are usually included in a License-out?
Common structures include Upfront payments, Development Milestones, Regulatory Milestones, Commercial Milestones, and Royalty sales commissions. The specific arrangements depend on the asset stage, regional rights, and the responsibilities undertaken by both parties.
Why does a License transaction require regional rights design?
Different countries and regions have different market sizes, regulatory systems, commercialization capabilities, and competitive environments. Through regional Licenses, companies can decide which markets to develop themselves and which markets to hand over to partners for development and commercialization based on their own capabilities.
How to screen for License-in projects?
License-in projects usually need to be comprehensively evaluated from aspects such as strategic fit, technical and clinical value, registration pathway, market size, competitive landscape, commercialization capabilities, and transaction price and structure.
When should international BD be launched?
International BD does not have to wait until the product is fully commercialized to be launched. Different asset stages can correspond to different cooperation strategies, but companies need to determine the appropriate BD timing based on their own financial capabilities, development risks, market strategies, and partner resources.
What is the difference between a License transaction and an M&A?
A License transaction usually transfers the rights to a specific product, technology, or region, rather than the ownership of the entire company. M&A, on the other hand, usually involves the transfer of control over the entire equity or assets of the company. The two have significant differences in terms of transaction scope, control, risk-taking, and capital investment.
Why do Chinese healthcare companies need international BD?
International BD can help companies connect with overseas R&D, registration, capital, industrial, and commercialization resources, and realize the international value of innovative assets through licensing, joint development, strategic cooperation, and other means.
How can T-Capital participate in License transactions?
Around License & BD transactions in the healthcare field, professional advisors can assist companies with asset sorting, partner screening, international BD strategy design, transaction structure design, business negotiations, and transaction execution. The specific scope of services should be determined according to the company’s asset type, target market, and transaction needs.